z-logo
Premium
Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction
Author(s) -
VAN DER KRABBEN M. D.,
ROSENDAAL F. R.,
VAN DER BOM J. G.,
DOGGEN C. J. M.
Publication year - 2008
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2008.02930.x
Subject(s) - medicine , myocardial infarction , risk factor , fibrinogen , odds ratio , factor vii , confidence interval , cardiology , coagulation , cohort
Summary.  Background:  The aim of this study was to examine whether genetic predisposition to high levels of coagulation factors influences the risk of developing fatal and non‐fatal arterial cardiovascular events in men with a first myocardial infarction (MI). Methods:  We performed a cohort study among 542 MI patients with a mean age of 56 years (range 32–70 years) at the time of the event. All of the men had a first MI between 1990 and 1996 and were followed until 1 September 2004. DNA was analyzed for polymorphisms of fibrinogen, prothrombin (factor II), factor V, factor VII and plasminogen activator inhibitor type 1, all of which are associated with gain of function of the protein. We collected information from hospital files and general practitioners on the occurrence of major arterial events. Results:  In total, 254 major arterial cardiovascular events occurred during a median follow‐up period of 11 years (range 0.2–15 years). The point estimates of the relative rates (RRs) of these events for the variant genotypes were all between 0.7 and 1.1 except for the prothrombin 20210A mutation: RR 1.8 (95% confidence interval 0.8–4.1). Conclusion:  These findings suggest that there is no association between coagulation factor polymorphisms, previously associated with plasma levels, and the risk of recurrent cardiovascular events.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here